A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
MK-1084-012
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Dr. Syafirin Ab Sani
CONTACT
SC: Hidayati Mohd Sha’ari
Contact No.: +6012-433 2344
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Colorectal Cancer
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Syafirin Bin Ab Sani
CONTACT
SC: HIDAYATI BINTI MOHD SHA’ARI
Raja Permaisuri Bainun Hospital
PRINCIPAL INVESTIGATOR
CHAN MING JUN
CONTACT
SC: Nurnabiha Syifaa Binti Nasir
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Fong Yian Ching
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
PRATHEPAMALAR A/P YEHGAMBARAM
CONTACT
SC: Rivisya Manickam
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
LEE CHEEN LENG
CONTACT
SC: Nur Rasyidah Muhammad
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
PRATHEPAMALAR A/P YEHGAMBARAM
CONTACT
SC: Rivisya Manickam
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
LEE CHEEN LENG
CONTACT
SC: Nur Rasyidah Muhammad
Raja Permaisuri Bainun Hospital, Ipoh
PRINCIPAL INVESTIGATOR
CHAN MING JUN
CONTACT
SC: Nurnabiha Syifaa Binti Nasir
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Fong Yian Ching